• darkblurbg

    TARGETING THE UNDERLYING

    CAUSES OF DIABETES

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
October 31, 2019
Annual Report
Annual Report 2018/2019
November 4, 2019
Stora Aktiedagen
Event by Aktiespararna, Gothenburg, Sweden.
November 21, 2019
Annual General Meeting
Annual General Meeting 2018/2019
January 22, 2020
Quarterly Report I
Quarterly Report 1 2019/2020

With Diamyd® in late stage development - the world’s furthest advanced antigen-specific diabetes therapeutic, Remygen® in early clinical phase, and a strong IP position, we look forward to further strengthening our value proposition during the forthcoming year.

Ulf Hannelius
President and CEO, Diamyd Medical AB

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.